Journals / European Journal of Rheumatology / 2016 / Cilt: 3 - Sayı: 3

Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis

Pages
95–100
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For SSc, the skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in all patients using high-resolution computed tomography and by performing pulmonary function tests.Results: The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively) demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/mL) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cluster of differentiation 163 (CD163) is a receptor that binds haptoglobin-hemoglobin complexes and is mainly expressed on macrophages and monocytes.
📊
Key Findings & Data:As a result of shedding, the extracellular portion of CD163 circulates in the blood as a soluble CD163 (sCD163).
💡
Conclusion & Impact:For SSc, the skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in all patients using high-resolution computed tomography and by performing pulmonary function tests.Results: The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively) demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/mL) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cluster of differentiation 163 (CD163) is a receptor that binds haptoglobin-hemoglobin complexes and is mainly expressed on macrophages and monocytes. As a result of shedding, the extracellular portion of CD163 circulates in the blood as a soluble CD163 (sCD163). This study aimed to measure serum sCD163 levels in patients with systemic sclerosis (SSc) and to assess its association with the clinical, laboratory, and radiological features of the disease.Material and Methods: We measured serum sCD163 levels in 24 patients with SSc and in 30 healthy controls. Complete history of the patients was recorded and thorough clinical, rheumatological, and dermatological examinations were performed. For SSc, the skin thickness score was scored according to the modified Rodnan skin score method and pulmonary involvement was assessed in all patients using high-resolution computed tomography and by performing pulmonary function tests.Results: The mean serum sCD163 levels in patients with diffuse and limited SSc (61.64±19.57 and 60.8±21.43 ng/mL, respectively) demonstrated a highly statistically significant increase compared with the mean serum levels in healthy controls (36.97±16.37 ng/mL) (p

🔖

Cite This Article

FOUAD, N., HASSAN, W. A. E. H., BARAKA, E. A. E., ELNADY, B. M., GOUDA, T. M. (2022). Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. European Journal of Rheumatology, Cilt: 3 - Sayı: 3, 95–100. https://ajindex.com/articles/511791

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Piela-Smith TH, Korn JH. Lymphocyte modula- tion of fibroblast function in systemic sclerosis. Clin Dermatol 1994; 12: 369-77. [CrossRef] Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Im- munol 2011; 11: 723-37. [CrossRef] Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35. [CrossRef] Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with local- ized scleroderma. Exp Dermatol 2009; 18: 727-9. [CrossRef] Mosser DM, Edwards JP. Exploring the full spec- trum of macrophage activation. Nat Rev Immu- nol 2008; 8: 958-69. [CrossRef] Gordon S. The macrophage: past, present and future. Eur J Immunol 2007; 37(Suppl 1): S9- 17. [CrossRef] Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. Nature 2001; 409: 198-201. [CrossRef] Hintz KA, Rassias AJ, Wardwell K, Moss ML, Mor- ganelli PM, Pioli PA, et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte he- moglobin scavenger receptor CD163. J Leukoc Biol 2002; 72: 711-7.
  2. Levy AP, Purushothaman KR, Levy NS, Purush- othaman M, Strauss M, Asleh R, et al. Downreg- ulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to in- traplaque hemorrhage and plaque vulnerabil- ity. Circ Res 2007; 101: 106-10. [CrossRef] Frings W, Dreier J, Sorg C. Only soluble form of the scavenger receptor CD163 acts inhibito- ry on phorbol ester activated T-lymphocytes, whereas membrane-bound protein has no ef- fect. FEBS Lett 2002; 526: 93-6. [CrossRef] Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, et al. A new macrophage differenti- ation antigen which is a member of the scaven- ger receptor superfamily. Eur J Immunol 1993; 23: 2320-5. [CrossRef] Kowal K, Silver R, Slawinska E, Bielecki M, Chy- czewski L, Kowal-Bielecka O. CD163 and its role in inflammation. Folia Histochem Cytobiol 2011; 49: 365-74. [CrossRef] Van den Hoogen F, Khanna D, Fransen J, John- son SR, Baron M, Tyndall A, et al. 2013 classifica- tion criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ar- thritis Rheum 2013; 65: 2737-47. [CrossRef] Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (system